Major ClientsNarrow moat

AbbVie (ABBV) — moat facet

Three wholesalers carry almost all of AbbVie's American sales, but the parties that set its prices are the benefit managers and governments who take $61 billion of rebates.

AbbVie's customers in the accounting sense are three wholesalers. In 2025 McKesson, Cardinal Health and Cencora accounted for substantially all of its pharmaceutical product sales in the United States, and no individual wholesaler accounted for more than 43% of American gross revenues1. The same three held 84% of AbbVie's receivables at the end of 20252.

Three wholesalers’ share of receivables (%)72%202075%202181%202484%2025AbbVie Forms 10-K FY2021 and FY2025
Three distributors hold most of the money owed.

But the wholesalers are distributors, not decision-makers. The parties that decide AbbVie's revenue are those who negotiate the price: Medicaid and Medicare rebates of $21,283 million, managed-care rebates of $22,307 million and wholesaler chargebacks of $17,710 million in 20253. Together they exceed AbbVie's net revenue4.

Revenue concentration and backlog concentration give different answers here. AbbVie says it has no single customer whose loss would have a material adverse effect, and that its order backlog is not material5. There is no disclosed backlog to be concentrated.

Geographically the base is concentrated: about 76% of 2025 net revenue was American6.

The concentration of receivables has risen steadily. The three wholesalers accounted for 72% of receivables at the end of 2020 and 75% at the end of 20217, 81% at the end of 2024 and 84% at the end of 20258. The trend reflects consolidation among American drug distributors rather than anything AbbVie did, but it means more of AbbVie's cash waits on fewer companies.

The customers are diffuse and the payers are powerful. The share of American gross revenue from the largest wholesaler, below 43% in 2025 against 39% in 2024910, is the concentration figure to follow; a rise would mean one distributor's terms matter more to AbbVie each year.

Moat trajectory: Holding steady

Wholesaler concentration steady; payer rebates rising.

The number that tests this moat
Reported
Largest wholesaler's cap on US gross revenues
Below 43% (2025); below 39% in 2024

Distributor concentration; a rise would give one wholesaler more leverage over terms.

Source: AbbVie Form 10-K, FY2025 ↗
Dig deeper
DIG DEEPER 01
McKesson, Cardinal Health and Cencora
Three wholesalers owed AbbVie 84% of its receivables at the end of 2025.
DIG DEEPER 02
The Payers Who Set the Net Price
Benefit managers and government programmes took $43.6 billion of rebates from AbbVie in 2025, equal to about 71% of its revenue.
DIG DEEPER 03
No Backlog and No Customer That Matters Alone
AbbVie has no backlog and no customer it could not lose, so its risk sits in two drugs, not in any buyer.
DIG DEEPER 04
Twenty-Four Percent Outside the United States
Only about a quarter of AbbVie's sales come from outside America, where its drugs earn far less.
References
  1. ReportedIn 2025 McKesson, Cardinal Health and Cencora accounted for substantially all of its pharmaceutical product sales in the United States, and no individual wholesaler accounted for more than 43% of American gross revenues.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedThe same three held 84% of AbbVie's receivables at the end of 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedThe parties that decide AbbVie's revenue are those who negotiate the price: Medicaid and Medicare rebates of $21,283 million, managed-care rebates of $22,307 million and wholesaler chargebacks of $17,710 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedTogether they exceed AbbVie's net revenue.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  5. ReportedAbbVie says it has no single customer whose loss would have a material adverse effect, and that its order backlog is not material.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  6. Moat Explorer calcGeographically the base is concentrated: about 76% of 2025 net revenue was American.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - revenue mix, concentration and geography. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  7. ReportedThe three wholesalers accounted for 72% of receivables at the end of 2020 and 75% at the end of 2021, 81% at the end of 2024 and 84% at the end of 2025.
    AbbVie Form 10-K for fiscal 2021 - Humira's share of revenue in 2019-2021 and rebate provisions for 2019-2021. — FY2021 · publ. February 2022 · source ↗
  8. ReportedThe three wholesalers accounted for 72% of receivables at the end of 2020 and 75% at the end of 2021, 81% at the end of 2024 and 84% at the end of 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  9. ReportedThe share of American gross revenue from the largest wholesaler, below 43% in 2025 against 39% in 2024, is the concentration figure to follow; a rise would mean one distributor's terms matter more to AbbVie each year.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  10. ReportedThe share of American gross revenue from the largest wholesaler, below 43% in 2025 against 39% in 2024, is the concentration figure to follow; a rise would mean one distributor's terms matter more to AbbVie each year.
    AbbVie Form 10-K for fiscal 2024 - product revenue for 2022-2024, product concentration, the CEO succession and the emraclidine impairment. — FY2024 · publ. February 2025 · source ↗
Sources
Generated September 25, 2026